The Company follows ASC 718 “Share-Based Payment”, which requires that all share based payments to employees, including stock options, be recognized as compensation expense in the consolidated financial statements based on their fair values and over the requisite service period. The Company recorded non-cash compensation expense relating to stock-based compensation of $0 and $5,000 for the three months ended March 31, 2019 and 2018, respectively ($0.00 per basic and diluted share for each period) and $152,000 and $141,000 for the nine months ended March 31, 2019 and 2018,

respectively ($0.01 per basic and diluted share each period).

In December 2012, the stockholders approved the 2012 Employee Stock Option Plan (the “2012 Employee Plan”). The 2012 Employee Plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 950,000 shares of the Company's common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options, which are intended to qualify as incentive stock options (“ISOs”), to valued employees. Any plan participant who is granted ISOs and possesses more than 10% of the voting rights of the Company's outstanding common stock must be granted an option with a price of at least 110% of the fair market value on the date of grant.

Under the 2012 Employee Plan, stock options may be granted to valued employees with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable, in whole or in part, at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At March 31, 2019, 68,000 stock options were outstanding, 33,300 stock options were exercisable and 797,900 stock options were available for grant under this plan

The fair value of each option granted during the nine months ended March 31, 2019 was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions:

	2019					2018
	Options			Weighted average exercise price		Options			Weighted average exercise price
Outstanding, beginning of year		57,200		$	7.09		70,600		$	5.84
Granted		24,000			15.28		25,000			9.01
Terminated/Lapsed		--			--		--			--
Exercised		(13,200	)		6.43		(20,600	)		5.55
Outstanding, end of period		68,000		$	10.11		75,000		$	6.97
Exercisable, end of period		33,300		$	7.84		43,200		$	6.34
Weighted average fair value at grant date of options granted	$	8.76				$	5.61
Total intrinsic value of options exercised	$	150,000				$	84,000
Total intrinsic value of options outstanding	$	723,000				$	292,000
Total intrinsic value of options exercisable	$	430,000				$	218,000

3,700 and 18,100 stock options were exercised during the three months ended March 31, 2019 and 2018, respectively. $3,000 and $45,000 of cash was received from option exercises during the three months ended March 31, 2019 and 2018, respectively, and the actual tax benefit realized for the tax deductions from option exercises was $3,000 and $0, respectively. 13,200 and 20,600 stock options were exercised during the nine months ended March 31, 2019 and 2018, respectively. $27,000 and $61,000 of cash was received from option exercises during the nine months ended March 31, 2019 and 2018, respectively, and the actual tax benefit realized for the tax deductions from option exercises was $7,000 and $0, respectively.

	Options outstanding						Options exercisable
Range of exercise prices	Number outstanding		Weighted average remaining contractual life		Weighted average exercise price		Number exercisable		Weighted average exercise price
$4.88-$16.16		68,000		7.7	$	10.11		33,300	$	7.84
		68,000		7.7	$	10.11		33,300	$	7.84

As of March 31, 2019, there was $253,000 o

f unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2012 Employee Plan. 0 and 5,000 options were granted during the three months ended March 31, 2019 and 2018, respectively.

24,000 and 25,000

options were granted during the nine months ended March 31, 2019 and 2018, respectively. 0 and 1,000 options vested during the three months ended March 31, 2019 and 2018, respectively. The total fair value of the options vesting during the nine months ended March 31, 2019 and 2018 under this plan was

$86,000 and $84,000, respectively.

In December 2012, the stockholders approved the 2012 Non-Employee Stock Option Plan (the “2012 Non-Employee Plan”). This plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 50,000 shares of the Company's common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options to non-employee directors and consultants to the Company and its subsidiaries.

Under the 2012 Non-Employee Plan, stock options may be granted with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable in whole or in part at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At March 31, 2019, 13,200 stock options were outstanding, 4,200 stock options were exercisable and no further stock options were available for grant under this plan.

	2019					2018
	Options			Weighted average exercise price		Options		Weighted average exercise price
Outstanding, beginning of year		27,800		$	6.85		14,200	$	4.69
Granted		—			—		15,000		8.70
Terminated/Lapsed		—			—		—		—
Exercised		(14,600	)		5.68		—		—
Outstanding, end of period		13,200		$	8.15		29,200	$	6.75
Exercisable, end of period		4,200		$	6.97		15,200	$	5.53
Weighted average fair value at grant date of options granted		n/a				$	8.70
Total intrinsic value of options exercised	$	167,000					n/a
Total intrinsic value of options outstanding	$	166,000				$	86,000
Total intrinsic value of options exercisable	$	58,000				$	63,000

3,600 and 0 stock options were exercised during the three months ended March 31, 2019 and 2018, respectively. No cash was received from option exercises during either of the three months ended March 31, 2019 or 2018 and the actual tax benefit realized for the tax deductions from option exercises was $10,000 and $0, respectively. 14,600 and 0 stock options were exercised during the nine months ended March 31, 2019 and 2018, respectively. No cash was received from option exercises during either of the nine months ended March 31, 2019 or 2018 and the actual tax benefit realized for the tax deductions from option exercises was $35,000 and $0, respectively.

	Options outstanding						Options exercisable
Range of exercise prices	Number outstanding		Weighted average remaining contractual life		Weighted average exercise price		Number exercisable		Weighted average exercise price
$4.37 - $8.70		13,200		8.2	$	8.15		4,200	$	6.97
		13,200		8.2	$	8.15		4,200	$	6.97

As of March 31, 2019, there was $50,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2012 Non-Employee Plan. No options were granted during either of the three months ended March 31, 2019 or 2018. 0 and 15,000 options were granted during the nine months ended March 31, 2019 and 2018, respectively. No options vested during either of the three months ended March 31, 2019 or 2018. No options vested during either of the nine months ended March 31, 2019 or 2018.

In December 2018, the stockholders approved the 2018 Non-Employee Stock Option Plan (the “2018 Non-Employee Plan”). This plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 50,000 shares of the Company's common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options to non-employee directors and consultants to the Company and its subsidiaries.

Under the 2018 Non-Employee Plan, stock options may be granted with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable in whole or in part at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At March 31, 2019, 20,000 stock options were outstanding, 4,000 stock options were exercisable and 30,000 stock options were available for grant under this plan.

	2019				2018
	Options		Weighted average exercise price		Options		Weighted average exercise price
Outstanding, beginning of year		—	$	—		—	$	—
Granted		20,000		16.20		—		—
Terminated/Lapsed		—		—		—		—
Exercised		—		—		—		—
Outstanding, end of period		20,000	$	16.20		—	$	—
Exercisable, end of period		4,000	$	16.20		—	$	—
Weighted average fair value at grant date of options granted	$	10.24				n/a
Total intrinsic value of options exercised		n/a				n/a
Total intrinsic value of options outstanding	$	91,000				n/a
Total intrinsic value of options exercisable	$	18,000				n/a

No stock options were exercised during the three months ended March 31, 2019 or 2018. No stock options were exercised during the nine months ended March 31, 2019 or 2018. No cash was received from option exercises during either of the three or nine months ended March 31, 2019 or 2018 and the actual tax benefit realized for the tax deductions from option exercises was $0 for each of these periods.

	Options outstanding						Options exercisable
Range of exercise prices	Number outstanding		Weighted average remaining contractual life		Weighted average exercise price		Number exercisable		Weighted average exercise price
$16.20-$16.20		20,000		9.7	$	16.20		4,000	$	16.20
		20,000		9.7	$	16.20		4,000	$	16.20

As of March 31, 2019, there was $164,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2018 Non-Employee Plan. No options were granted during the three months ended March 31, 2019 or 2018. 20,000 and 0 options were granted during the nine months ended March 31, 2019 and 2018, respectively. No options vested during either of the three months ended March 31, 2019 or 2018. The total fair value of the options vesting during the nine months ended March 31, 2019 and 2018 under this plan was $41,000 and $0, respectively.

In December 2002, the stockholders approved the 2002 Employee Stock Option Plan (the “2002 Employee Plan”). This plan expired in October 2012. This plan authorized the granting of awards, the exercise of which would allow up to an aggregate of 1,836,000 shares of the Company's common stock to be acquired by the holders of such awards. Under this plan, the Company may have granted stock options, which were intended to qualify as incentive stock options (ISOs), to key employees. Any plan participant who was granted ISOs and possessed more than 10% of the voting rights of the Company's outstanding common stock must have been granted an option with a price of at least 110% of the fair market value on the date of grant.

Under the 2002 Employee Plan, stock options have been granted to key employees with a term of 10 years at an exercise price equal to the fair market value on the date of grant and are exercisable in whole or in part at 20% per year from the date of grant. At March 31, 2019, no stock options were outstanding or exercisable and no further stock options were available for grant under this plan after the plan expired in October 2012.

No options were exercised during either of the three months ended March 31, 2019 or 2018. 0 and

5,000 stock options were exercised during the nine months ended March 31, 2019 and 2018, respectively. The 5,000 exercises were settled in cashless exercises by exchanging 2,815 shares of the Company’s common stock which were retired and returned to unissued status. No cash was received from option exercises during either of the three or nine months ended March 31, 2019 and 2018 and the actual tax benefit realized for the tax deductions from option exercises was $0 for each of these periods.